ReviewSN comprehensive clinical medicine2020
Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials.
Review in SN comprehensive clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Efficacy of tocilizumab in the treatment of COVID-19: An umbrella review.Reviews in medical virology · 2022Pooled it
- Current evidence for COVID-19 therapies: a systematic literature review.European respiratory review : an official journal of the European Respiratory Society · 2021Pooled it
- The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis.Canadian respiratory journal · 2020Pooled it
- Effectiveness and safety of cyclosporine A in moderate to severe COVID-19: a randomized, open-label trial.Scientific reports · 2026Trial
- Article
- Plasma cell-free DNA promise monitoring and tissue injury assessment of COVID-19.Molecular genetics and genomics : MGG · 2023Article
- Infections associated with SARS-CoV-2 exploited via nanoformulated photodynamic therapy.ADMET & DMPK · 2023Review
- Active site prediction of phosphorylated SARS-CoV-2 N-Protein using molecular simulation.Informatics in medicine unlocked · 2022Article
- Effects of hydroxychloroquine and favipiravir on clinical course in outpatients with COVID-19Turkish journal of medical sciences · 2021Article
- Scoping insight on antiviral drugs against COVID-19.Arabian journal of chemistry · 2021Review
- COVID-19 Repeated Convalescent Plasma Collection: Analysis of 149 Donations from 88 French Military Health Workers.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2021Article
- Palliative Care for Patients on Extracorporeal Membrane Oxygenation for COVID-19 Infection.The American journal of hospice & palliative care · 2021Article
- A review of potential suggested drugs for coronavirus disease (COVID-19) treatment.European journal of pharmacology · 2021Review
- Pharmacological Treatment Options for Coronavirus Disease-19 in Renal Patients.International journal of nephrology · 2021Review
- Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review.SN comprehensive clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The following systematic review and meta-analysis compile the current data regarding human controlled COVID-19 treatment trials. An electronic search of the literature compiled studies pertaining to human controlled treatment trials with COVID-19. Medications assessed included lopinavir/ritonavir, arbidol, hydroxychloroquine, tocilizumab, favipiravir, heparin, and dexamethasone. Statistical analyses were performed for common viral clearance endpoints whenever possible. Lopinavir/ritonavir showed no significant effect on viral clearance for COVID-19 cases (OR 0.95 [95% CI 0.50-1.83]). Hydroxychloroquine also showed no significant effect on COVID-19 viral clearance rates (OR 2.16 [95% CI 0.80-5.84]). Arbidol showed no 7-day (OR 1.63 [95% CI 0.76-3.50]) or 14-day viral (OR 5.37 [95% CI 0.35-83.30]) clearance difference compared to lopinavir/ritonavir. Review of literature showed no significant clinical improvement with lopinavir/ritonavir, arbidol, hydroxychloroquine, or remdesivir. Tocilizumab showed mixed results regarding survival. Favipiravir showed quicker symptom improvement compared to lopinavir/ritonavir and arbidol. Heparin and dexamethasone showed improvement with severe COVID-19 cases requiring supplemental oxygenation. Current medications do not show significant effect on COVID-19 viral clearance rates. Tocilizumab showed mixed results regarding survival. Favipiravir shows favorable results compared to other tested medications. Heparin and dexamethasone show benefit especially for severe COVID-19 cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.